August 2012
-
Glenmark Pharmaceuticals has submitted an NDA for Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in patients aged 12 and older, the company said. In December 2017, the company announced… Read more . . .
-
According to GSK, the FDA has approved the company’s sNDA for the use of Arnuity Ellipta fluticasone furoate DPI for the treatment of asthma in children aged 5-11 years. Arnuity Ellipta was approved by the… Read more . . .
-
Galecto Biotech, which is developing an inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), has hired former GSK VP and Head of the Fibrosis & Lung Injury Discovery Performance Unit Richard Marshall… Read more . . .
-
Inhaler monitoring company Adherium has announced that its Smartinhaler platform has been rebranded as “Hailie.” The rebranding includes includes the Hailie asthma and COPD tracking app and Hailie sensors, which will soon launch in the… Read more . . .
-
Liquidia Technologies has named Jeri Thomas as its new Senior VP Commercial, responsible initially for commercial plans for the company’s LIQ861 treprostinil DPI, which is currently in Phase 3 development for the treatment of pulmonary… Read more . . .
-
The FDA has accepted Insned’s NDA for ALIS (amikacin liposome inhalation suspension) for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC), with a PDUFA date of September 28, 2018,… Read more . . .
-
The FDA informed Perrigo during a May 10, 2018 teleconference that the agency will issue a complete response letter to the company’s ANDA for its generic version of Teva’s ProAir albuterol MDI, Perrigo said. As… Read more . . .
-
MannKind Corporation announced that it has signed a deal with Cipla for marketing and distribution of Afrezza inhaled insulin in India. Cipla will be responsible for getting regulatory approval in India and will pay MannKind… Read more . . .
-
The Medical Devices Group at the University of Cape Town has designed a device to significantly reduce the force required to actuate an inhaler, the university has announced. The device, called “Easy Squeezy,” fits over… Read more . . .
-
TFF Pharmaceuticals, which recently announced that it had raised $14 million for the development of DPI formulations, has named former Arno Therapeutics CEO Glenn Mattes as its new Chief Executive Officer. Mattes’s career includes management… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland